Newcastle Upon Tyne, United Kingdom
Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies.
Through our highly experienced ADC Development Team, we are building a pipeline of best in class ADCs with superior therapeutic index (TI).
Our approach is to develop the best ADCs for each tumour or tumour sub-type through careful selection of the right combinations of payload, linker and conjugation chemistry.
Iksuda has built a portfolio of ADC assets including;
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Iksuda Therapeutics on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.